Modification of induced ischaemic pain by placebo electrotherapy

Quantifying the analgesic effect of placebo electrotherapy is an important part of understanding the placebo response in physiotherapy. This repeated measures study of induced ischaemic pain compared reports of pain threshold, pain tolerance, and pain endurance under three conditions: control, placebo interferential, and placebo TENS. Both of the placebo conditions significantly delayed the report of pain threshold. Placebo interferential also delayed pain tolerance. Each placebo condition reduced pain intensity in the 6th minute. Only placebo TENS reduced pain at the 9th minute of ischaemic pain. The nature of pain reduction in the placebo conditions suggests that analgesia was due to learned expectancies and endogenous opioid release. Further research into the impact of positive expectancies of pain relief in our patients could clarify the efficacy of physiotherapy outcomes for pain.

TACE inhibition: a new approach to treating inflammation

Clinical trials showing the benefits of reducing the effects of TNF-alpha in rheumatoid arthritis have highlighted the key role of the cytokine TNF-alpha in this inflammatory condition. A new approach to reducing the effects of TNF-alpha is to decrease its synthesis by inhibiting TNF-alpha converting enzyme with GW3333. In rat models of arthritis, GW3333 has some beneficial effects. Further longer-term studies of GW3333 in animal models are required to determine whether its benefit is maintained. TACE inhibition may represent a new approach to treating inflammation.

The therapeutic potential of dopamine modulators on the cardiovascular and renal systems

In the periphery, physiological dopamine increases renal blood flow, decreases renal resistance and acts on the kidney tubule to enhance natriuresis and diuresis. The loss of dopamine function may be involoved in the deterioration in kidney function associated with ageing and may have a role in the pathogenesis of hypertension and diabetes. Intravenous dopamine is used as a positive inotrope in the treatment of acute heart failure and cardiogenic shock and as a diuretic in renal failure. The clinical uses of dopamine are limited, as it must be given intravenously, and also has widespread effects. The levels of peripheral dopamine can be increased by the administration of L-dopa to increase synthesis, prodrugs to release dopamine (docarpamine, glu-dopa) or by inhibiting the breakdown of dopamine (nitecapone). Preliminary clinical trials suggest that docarpamine may be useful in patients with low cardiac output syndrome after cardiac surgery and in refractory cirrhotic ascites. Ibopamine is an agonist at dopamine D1 and D2 receptors, which may retard the progression of chronic renal failure. Gludopa is selective for the kidney thus avoiding widespread side effects. The early clinical studies with ibopamine as a diuretic in heart failure were favourable but the subsequent large mortality study showed that ibopamine increased mortality. Fenoldopam is a selective dopamine D1 receptor agonist. Intravenous fenoldopam may be useful in the treatment of hypertension associated with coronary artery bypass surgery or in hypertensive emergencies. Although our understanding of physiological and pathological roles of peripheral dopamine has been increasing rapidly in recent times, we still need more information to allow the design of clinically useful drugs that modify these roles. One priority is an orally-active selective dopamine D1 receptor agonist.

The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system

Clinical trials have established bosentan, an orally active non-selective endothelin (ET) receptor antagonist, as a beneficial treatment in pulmonary hypertension. Trials have also shown short-term benefits of bosentan in systemic hypertension and congestive heart failure. However, bosentan also increased plasma levels of ET-1, probably by inhibiting the clearance of ET-1 by endothelin type B (ET.) receptors, and this may mean its effectiveness is reduced with long-term clinical use. Preliminary data suggests that selective endothelin type A (ETA) receptor antagonists (BQ-123, sitaxsentan) may be more beneficial than the non-selective ET receptor antagonists in heart failure, especially when the failure is associated with pulmonary hypertension. Experimental evidence in animal disease models suggests that non-selective ET or selective ETA receptor antagonism may have a role in the treatment of athero-sclerosis, restenosis, myocarditis, shock and portal hypertension. In animal models of myocardial infarction and/or reperfusion injury, non-selective ET or selective ETA receptor antagonists have beneficial or detrimental effects depending on the conditions and agents used. Thus clinical trials of the nonselective ET or selective ETA receptor antagonists in these conditions are not presently warranted. Several selective endothelin-converting enzyme inhibitors tors have been synthesised recently, and these are only beginning to be tested in animal models of cardiovascular disease, and thus the clinical potential of these inhibitors is still to be defined.

Will chymase inhibitors be the next major development for the treatment of cardiovascular disorders?

Chymase is contained in the secretory granules of mast cells. In addition to the synthesis of angiotensin II, chymase is involved in transforming growth factor-beta activation and cleaves Type I procollagen to produce collagen. NK301 and BCEAB are orally-active inhibitors of chymase. NK301 was tested in a dog model of vascular intimal hyperplasia after balloon injury and shown to reduce the increased chymase activity in the injured arteries and prevent intimal thickening. In a hamster model of cardiac fibrosis associated with cardiomyopathy, BCEAB reduced the increased cardiac chymase activity in cardiomyopathy and reduced fibrosis. Chymase inhibitors may be an important development for the treatment of cardiovascular injury associated with mast cell degranulation.

Cobertura tem??tica do Reposit??rio Institucional da ENAP

A Cobertura Tem??tica do Reposit??rio Institucional da ENAP ?? uma linguagem document??ria que objetiva identificar as grandes ??reas tem??ticas existentes no contexto institucional da ENAP e refletir os conceitos utilizados na ??rea de conhecimento Administra????o P??blica, observando os limites de atua????o da escola. Tal estudo permitir?? um melhor controle dos termos autorizados nos diversos sistemas de informa????o da ENAP e parcerias, inclusive o Reposit??rio Institucional da ENAP.

Teleassist??ncia em rede para regi??es remotas: melhorando o acesso da popula????o ?? aten????o especializada em sa??de

A iniciativa, implementada em Minas Gerais, ?? considerada uma das maiores experi??ncias de teleassist??ncia sustent??vel no mundo, servindo de modelo para outras a????es similares no Brasil e na Am??rica Latina. Sua cria????o representa uma nova atividade econ??mica, gerando um novo campo de trabalho e uma nova ??rea de pesquisa, tanto na sa??de quanto na ??rea de TI. Os resultados alcan??ados impactaram positivamente a melhoria do acesso da popula????o a servi??os especializados e a fixa????o de profissionais em localidades remotas

Modelo de gest??o do ambiente de TI aplicado ao IBGE

A arquitetura de inform??tica do IBGE busca refletir a evolu????o das Tecnologias da Informa????o e de Comunica????o (TIC) e vem sendo modificada ao longo dos anos, de maneira a manter - se um equil??brio entre os anseios e diretrizes institucionais e governamentais. A partir do aprendizado e do sucesso obtidos no Censo Demogr??fico 2010, o IBGE inova agora na forma de administrar sua ??rea de TIC, baseado em software especialista adquirido.O IBGE se beneficia da administra????o dos bens de inform??tica, da responsabilidade sobre contratos, da gest??o do patrim??nio, do uso otimizado dos softwares comerciais, da agilidade de obten????o de informa????es sobre o parque computacional instalado, do monitoramento on-line dos servi??os oferecidos pela TI, da economia de gastos com viagens para suporte t??cnico dentro dos estados e entre os mesmos, da reeduca????o de funcion??rios quanto ao uso de tecnologias, da forma organizada e planejada de trabalho e, portanto, da gest??o p??blica das TIC

Projeto porto sem papel

O setor portu??rio envolve uma grande diversidade de usu??rios e ??rg??os intervenientes, cada um com suas normas e processos pr??prios. Tal situa????o, associada ao fato de que todo o fluxo de informa????es e documentos solicitados pelos ??rg??os aos usu??rios era realizado em papel, n??o permitia clareza e efici??ncia na troca de informa????es. A falta de dados confi??veis e tempestivos tamb??m n??o permitia efetividade na gest??o e planejamento do setor. Nesse contexto, foi implantado, na fase inicial do Porto Sem Papel, um sistema que permitia a troca de informa????es e documentos digitais entre os usu??rios e os diversos ??rg??os intervenientes. Assim, os fluxos de informa????es e documentos, que antes eram realizados em papel, passaram a ser realizados digitalmente, dando agilidade e transpar??ncia aos processos. Cabe destacar que todas as informa????es est??o presentes agora em uma base ??nica de dados, o que permite a realiza????o de an??lises que subsidiem a gest??o e a melhoria de processos no setor portu??rio

Sistema de Gest??o de Conv??nios e Contratos de Repasse (Siconv). Um novo paradigma nas transfer??ncias volunt??rias da Uni??o

O Sistema de Gest??o de Conv??nios e Contratos de Repasse (Siconv) ?? a iniciativa do Governo Federal respons??vel por todo o ciclo de vida dos conv??nios, contratos de repasse e termos de parceria, no qual s??o registrados os atos, desde a formaliza????o da proposta at?? a presta????o de contas final. O Siconv inova no modelo de gest??o, proporciona celeridade aos procedimentos e desburocratiza as atividades fins, com foco na substitui????o do processo f??sico pelo eletr??nico e no registro de todos os procedimentos, o que permite maior transpar??ncia na execu????o das transfer??ncias volunt??rias da Uni??o. Destaca- se ainda que a disponibiliza????o do sistema aos usu??rios e tamb??m para a sociedade por meio do endere??o eletr??nico www.convenios.gov.br deve ser considerada como grande fator de inova????o, uma vez que, mesmo indiretamente, se apresenta como mais uma ferramenta de controle social.

Almoxarifado virtual: uma proposta de sustentabilidade por contrata????o de gerenciamento de meios

A iniciativa opera a partir da presta????o de um servi??o continuado de gerenciamento de meios. Em s??ntese, o ??rg??o parou de adquirir materiais de escrit??rio e de combate a inc??ndio e passou a operar com um almoxarifado terceirizado que fornece insumos de expediente, processamento de dados e combate a inc??ndios de seu pr??prio almoxarifado, num sistema similar a um stop shop, al??m de controlar os estoques de pronto uso de cada unidade e fazer o seu ressuprimento. Cada unidade da autarquia possui uma cota aut??noma de pedidos, num baixo valor em periodicidade mensal. Com tal iniciativa, as unidades se mant??m supridas o ano todo, sem desperd??cios e sem estoques, fazendo os seus pedidos no almoxarifado virtual e customizando suas cestas de necessidades de produtos para a produ????o processual e o atendimento sazonal das emerg??ncias ambientais